1. Home
  2. PRTA vs TRC Comparison

PRTA vs TRC Comparison

Compare PRTA & TRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.21

Market Cap

501.2M

Sector

Health Care

ML Signal

HOLD

Logo Tejon Ranch Co

TRC

Tejon Ranch Co

HOLD

Current Price

$18.80

Market Cap

476.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTA
TRC
Founded
2012
1843
Country
Ireland
United States
Employees
67
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
501.2M
476.6M
IPO Year
2013
1995

Fundamental Metrics

Financial Performance
Metric
PRTA
TRC
Price
$9.21
$18.80
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
442.2K
93.5K
Earning Date
05-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$814,000.00
$37,830,000.00
Revenue This Year
$1,111.38
$2.31
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.32
$15.04
52 Week High
$13.95
$19.53

Technical Indicators

Market Signals
Indicator
PRTA
TRC
Relative Strength Index (RSI) 48.10 68.43
Support Level $9.07 $15.56
Resistance Level $9.59 $19.20
Average True Range (ATR) 0.50 0.59
MACD 0.02 0.11
Stochastic Oscillator 40.35 70.84

Price Performance

Historical Comparison
PRTA
TRC

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About TRC Tejon Ranch Co

Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.

Share on Social Networks: